🇺🇸 Cordarone in United States

FDA authorised Cordarone on 18 December 2002

Marketing authorisations

FDA — authorised 18 December 2002

  • Application: ANDA075424
  • Marketing authorisation holder: TARO
  • Indication: Labeling
  • Status: approved

Read official source →

FDA — authorised 3 May 2005

  • Application: ANDA075389
  • Marketing authorisation holder: DR REDDYS LABS SA
  • Indication: Labeling
  • Status: approved

Read official source →

FDA — authorised 15 January 2009

  • Application: ANDA077161
  • Marketing authorisation holder: GLAND PHARMA LTD
  • Indication: Labeling
  • Status: approved

Read official source →

FDA — authorised 31 May 2013

  • Application: ANDA076362
  • Marketing authorisation holder: TARO
  • Indication: Labeling
  • Status: approved

Read official source →

FDA — authorised 25 October 2017

  • Application: ANDA204550
  • Marketing authorisation holder: EUGIA PHARMA
  • Status: approved

Read official source →

Cordarone in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Cardiovascular approved in United States

Frequently asked questions

Is Cordarone approved in United States?

Yes. FDA authorised it on 18 December 2002; FDA authorised it on 3 May 2005; FDA authorised it on 15 January 2009.

Who is the marketing authorisation holder for Cordarone in United States?

TARO holds the US marketing authorisation.